Bristol-Myers Squibb Company (BMY)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	16,631,000	17,306,000	16,949,000	16,424,000	16,866,000	16,574,000	16,787,000	17,616,000	17,718,000	17,091,000	17,622,000	17,410,000	16,199,000	20,985,000	24,246,000	27,052,000	30,745,000	28,040,000	24,219,000	21,090,000
Revenue (ttm)	US$ in thousands	48,300,000	47,435,000	46,509,000	45,534,000	45,006,000	44,935,000	45,187,000	45,848,000	46,159,000	46,738,000	47,144,000	46,960,000	46,385,000	45,468,000	44,384,000	42,810,000	42,518,000	39,395,000	34,862,000	31,006,000
Gross profit margin		34.43%	36.48%	36.44%	36.07%	37.48%	36.88%	37.15%	38.42%	38.38%	36.57%	37.38%	37.07%	34.92%	46.15%	54.63%	63.19%	72.31%	71.18%	69.47%	68.02%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $16,631,000K ÷ $48,300,000K
= 34.43%

The gross profit margin of Bristol-Myers Squibb Company has shown fluctuating trends over the past few years. Starting from March 31, 2020, the gross profit margin was strong at 68.02%, indicating the company's ability to control production costs and generate a significant profit from its sales.

There was a steady increase in the gross profit margin over the next few quarters, reaching a peak of 72.31% by December 31, 2020. This upward trend suggested improved operational efficiency and profitability during that period.

However, from March 31, 2021, the gross profit margin began to decline, dropping to 54.63% by June 30, 2021, and further down to 34.92% by December 31, 2021. These decreasing margins could indicate challenges such as increasing production costs, pricing pressures, or changes in the sales mix.

The gross profit margin continued to fluctuate between 34% and 38% over the subsequent quarters until December 31, 2024, where it stood at 34.43%. These figures suggest that Bristol-Myers Squibb may be facing ongoing challenges in maintaining consistent profitability and controlling costs effectively.

Overall, the analysis of Bristol-Myers Squibb's gross profit margin highlights fluctuations in the company's ability to generate profits from its core operations over the reviewed period, indicating the need for a closer evaluation of its cost structure and revenue generation strategies.